Polyp of middle ear

Summary

Polyp of middle ear (MONDO:0004223) is a disease. A subtype of polyp — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	polyp of middle ear
Mondo ID	MONDO:0004223
DOID	DOID:7439
ICD-10-CM	H74.4
ICD-11	116272899
NCIT	C6933
SNOMED CT	73103007
UMLS	C0271466
MedGen	124403
Anatomy (UBERON)	UBERON:0001756
Is cancer (heuristic)	no

Also known as: middle Ear polyp · middle ear polyp · polyp of the middle ear

Disease family

This is a subtype of polyp. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › polyp › polyp of middle ear

Related subtypes (20): epulis, uterine polyp, intestinal polyp, hyperplastic polyp, nasal cavity polyp, stomach polyp, neoplastic polyp, polyp of ureter, polyp of large intestine, polyp of vagina, polyp of vulva, polyp of external auditory canal, polyp of sphenoidal sinus, polyp of frontal sinus, polyp of maxillary sinus, polyp of gallbladder, polyp of ethmoidal sinus, polyp of vocal cord, gastrointestinal polyp, fibroepithelial polyp

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.